Purpose To investigate the expression of GRIM-19 (Gene associated with retinoid-interferon-induced mortality 19) in mouse oocytes and preimplantation embryos, and to study the effect of GRIM-19 on the developmental competence of mouse oocytes and embryos. Methods GRIM-19 was evaluated at both mRNA and protein levels. The expression of GRIM-19 gene was downregulated in mouse oocytes cultured in vitro by specific small interfering RNA (siRNA) injection, while the activity of GRIM-19 was decreased by microinjection of a GRIM-19 antibody into the cytoplasm of germinal vesicle (GV) oocytes. Oocytes matured in vitro were then fertilized by intracytoplasmic sperm injection (ICSI), followed by observation and evaluation of fertilization rate, cleavage rate, blastocyst formation rate and implantation rate.
Introduction
Oocyte quality, which accounts for developmental competence, is the most crucial factor affecting the chance of success in the treatment course of in vitro fertilization and embryo transfer (IVF-ET) [1] [2] [3] . It has been demonstrated that the abnormal structure and function of oocyte's mitochondria could reduce the quality and the fertilization competence of oocytes, one of the key reasons for infertility and low reproductive ability [4] [5] [6] [7] . Mitochondria are maternally inherited and their replication does not begin until after implantation [8] . In order to improve oocyte quality, cytoplasm and mitochondria transfer have been reported to be an effective treatment procedure. And, more than 30 babies have been born with this technique [9, 10] . However, the use of this method raises concerns including mitochondrial heteroplasmy and the spread of mitochondrial genetic disease [11] . In addition, increased mitochondria number in oocytes may also influence the development of embryo [12] . Thus, a major problem revolves around improving mitochondrial function of oocytes.
Grim-19 (Gene associated with retinoid-interferon-induced mortality 19 ) was originally identified as a critical regulatory protein for interferon-beta and retinoic acid-induced cell death [13] [14] [15] [16] . It has been mapped to human chromosome 19p13.2, and codes for a novel 16 kDa protein. It was also demonstrated that GRIM-19 is a functional subunit of mitochondrial respiratory chain complex I, and plays an essential role in the assembly and enzymatic activity of complex I [17] [18] [19] . Therefore, GRIM-19 plays a dual protein function involved in cell death and mitochondrial metabolism. Huang et al. [18] also demonstrated that homozygous deletion mutation of the Grim-19 gene causes embryonic lethality at embryonic day 9.5. GRIM-19 −/− blastocysts showed retarded growth in vitro and display abnormal mitochondrial structure, morphology and cellular distribution. However, the expression and function of GRIM-19 during oogenesis and early embryogenesis is still unknown.
The present study aims to: 1) investigate the expression of GRIM-19 in mice oocytes and preimplantation embryos; 2) evaluate the function of GRIM-19 on mice oocytes maturation, early embryo development and embryo implantation.
Materials and methods

Animals and experiment protocols
All experimental protocols and animals used were approved by the Animal Research Ethical Committee, Qilu Hospital of Shandong University. All experiments were performed on Kunming mice, aged between 8 and 12 weeks and weighing 30-35 g, purchased from Shandong University (scxk LU 20090001), and bred in our facilities (which were maintained at 21±2°C and 55±10 % relative humidity on a 12 h light/ dark cycle). All groups with sample size in this study are listed in Table 1. Ovary stimulation, oocyte and embryo harvesting Ovaries were stimulated with FSH (purified follicle stimulating hormone; Livzon Group, Zhuhai, China; 10 IU per dose) to superovulate followed by 10 IU human chorionic gonadotrophin (hCG; Livzon Group, Zhuhai, China) 46-48 h later. Germinal vesicle (GV) oocytes were collected from ovaries 46-48 h after FSH injection. Milrinone, which increases cAMP, was used to inhibit germinal vesicle breakdown (GVBD). MII oocytes (with the first polar body) and MI oocytes (with no PB or nuclear structure) were collected 12 h post hCG injection. Embryos at 2-cell, 4-cell, 8-cell, morula, and blastocyst stages were obtained after successful mating with males at 46-48, 55, 65, 75, and 84-86 h after post-hCG, respectively. Pregnancy was confirmed the following morning by the presence of a vaginal plug. Mice were sacrificed by cervical dislocation for oocytes and embryos collecting.
Realtime PCR mRNA expression of grim-19 was detected using realtime PCR. Oocytes (GV, MI and MII) and embryos of each stage (2-to 8-cell, morula, blastocyst) were pooled in groups for total RNA extraction (n=50 for each stage). The zona pellucida was removed chemically by exposure to Tyrode's solution (Irvine Scientific Santa Ana, California, USA). Total RNA was isolated using the RNeasy micro kit (Qiagen, Valencia, California, USA) according to the manufacturer's protocol.
cDNA was produced and amplified using the cDNA synthesis kit (Takara, DaLian, China) by random hexamers according to the manufacturer's instructions. The nucleotide sequences of primer pairs for GRIM-19 were designed as follows: Forward-5′-TCGGGGACTGTCGGGGTAC-3′, Reverse-5′-AGGGTCCTCCGGTCCTTCT-3′. Histone H2a family member Z (H2afz) was used as a normalizer, because its expression pattern has been previously measured and established to be stable in mouse oocytes and preimplantation embryos under different conditions [20, 21] . All PCR reactions were performed in triplicate in a 20 μl reaction volume on the quantitative real-time PCR StepOne plus system (ABI, Carlsbad, California, USA) using the SYBR Premix Ex Taq™ II (Takara, DaLian, China). The reaction mixtures were subjected to an initial denaturation of 95°C for 10 min, followed by 36 cycles of 95°C for 5 s, 60°C for 30 s, and during which fluorescence was measured and was followed by a melt curve analysis to confirm a single gene-specific peak and to detect primer/dimer formation. A negative template control of DEPC water was used to ensure that there was no nucleotide contamination. The relative amount of each mRNA was determined using the 2 −△(△CT) method and calculated by dividing the intensity. Data were normalized based on H2afz transcript levels, and three independent experiments were carried out.
Western blotting
Protein expression was analyzed by western blotting. Western blot analysis was performed as described previously [18] . Briefly, embryos (n=200 for each stage) were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.2, 150 mM NaCl, 1 % deoxycholic acid, 1 % Triton X-100, 0.1 % SDS, 0.25 mM EDTA) with Phenylmethanesulfonyl fluoride. The lysate was separated by SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membrane. The membrane was blocked with phosphate-buffered saline (PBS) containing 0.1 % Tween 20 and 5 % skimmed milk before it was incubated with the appropriate primary (rabbit polyclonal antibody against GRIM-19, Santa, California, USA, diluted to 1:2000) and secondary antibodies (HRP-labeled Goat AntiRabbit, Beyotime, Nantong, China, diluted to 1:500). Immunoreactivity was detected using the appropriate peroxidaselinked secondary antibody and enhanced chemiluminescence (ECL) detection reagent. Three independent experiments were carried out.
Mitotracker staining
The mitochondria were visualized by Mitotracker® Red (Invitrogen, California, USA). Embryos were incubated with 400 nM Mitotracker® Red for 20 min. After staining, embryos were washed in fresh, pre-warmed G1. Then the medium was removed carefully, and replaced with freshly prepared, prewarmed buffer containing 4 % formaldehyde. The embryos were fixed at room temperature for 30 min.
Immunohistochemistry
The subcellular localization of GRIM-19 was investigated by immunofluorescent staining. Embryos were fixed in 4 % paraformaldehyde for 30 min at room temperature and permeabilized for 20 min in 0.5 % Triton X-100. After being blocked with 5 % goat serum (Zhongshan, Beijing, China) in PBS overnight at 4°C, oocytes and embryos were exposed to primary antibodies (rabbit polyclonal antibody against GRIM-19, Santa, America, diluted to 1:100) for 2 h followed by washed 3 times in PBS for 10 min each. Then oocytes and embryos were incubated for 2 h at room temperature in the presence of 1:100 diluted secondary antibodies (FluoresceinConjugated AffiniPure Goat Anti-Rabbit IgG, zhongshan, Beijing, China). After rinsing 3 times in PBS for 10 min each, oocytes and embryos were stained with 4′, 6-diamidino-2-phenylindole (DAPI) (Beyotime, Nantong, China) for 3 min. For negative controls, oocytes and embryos incubated with only the secondary primary antibody.
Microinjection of GRIM-19 siRNA into GV oocytes
Oocytes with germinal vesicle were microinjected with siRNAs using a micromanipulation operating system (RI, Research Instrument Company, England) within 30 min. siRNA duplex oligoribonucleotides targeting the coding region of GRIM-19 (GenBank Accession no: NM023312) were obtained from Invitrogen (Carlsbad, California, USA). 5-10 pl of 50 μM control siRNA or specific GRIM-19 siRNA (GRIM-19 siRNA (1): GCAATGCCAACTTCGGCTT, GRIM-19 siRNA (2): GGCTTCACCTGGTACACTT) was microinjected into the cytoplasm. Non-silencing siRNA nucleotides were used as a negative control. After microinjection, the oocytes were arrested at the GV stage for 16 h in G1-containing 2.5 μM milrinone. Real time PCR and western blotting were performed to detect the reduction degree of GRIM-19 mRNA and protein in mouse oocytes after injection, and Gapdh was used as a normalizer. Then, the oocytes were transferred to IVM medium (Quinn's, USA) at 37°C with 5 % CO 2 .
Microinjection of GRIM-19 antibody into GV oocytes
Oocytes with germinal vesicle were microinjected with antibodies using a micromanipulation operating system (RI, Research Instrument Company, England). GRIM-19 antibody (stock solution, 200 ug/ml, rabbit polyclonal, Santa Cruz Biotechnology, Santa Cruz, California, USA) was microinjected into the cytoplasm of GV oocytes as described by Dai et al. [22] . Rabbit normal IgG-injected (Santa Cruz, California, USA) oocytes and untreated oocytes were used as controls to assess injection damage. The microinjection experiments were done 20 replicates. Microinjection was completed in 30 min, with volume of about 7 pl per oocyte. To determine in vitro maturation rate, the microinjected GV oocytes were cultured in IVM medium in a 5 % CO 2 incubator at 37°C for 14 h.
In vitro maturation, fertilization and blastocytst culture
GVoocytes were cultured individually in 50 μL IVM medium droplets at 37°C with 5 % CO 2 . The maturity of oocytes was evaluated after 14 h culture. In-vitro matured oocytes (MII) were inseminated by ICSI using mice spermatozoa collected from the cauda epididymidis of KM males (>12 weeks) and purified as described elsewhere [23] . After injection, oocytes were cultured individually in 50-μL droplets of embryo culture medium (G-1, Vitrolife, Sweden) at 37°C under 5 % CO 2 . Fertilization was inspected for two pronucleus formation (2PN) under an inverted microscope 16-18 h after injection and embryos were cultured until blastocyst stage at day 4.
Blastocyst transfer
To determine the influence of GRIM-19 on implantation competency, blastocysts in GRIM-19 siRNA injected group, GRIM-19 antibody injected group and control group were transferred to recipient mice. Hyperstimulation was accomplished with the same FSH and hCG as described above. Pseudopregnancy mice were obtained by witnessed copulation with vasectomied mice, and 28 oseudopregnancy mice were used. To perform the transfers, pseudopregnancy mice were anesthetized by 50 mg/kg pentobarbital sodium subcutaneous injection. Ten blastocysts were transferred to the each uterine horn of day-2.5 pseudopregnant mice [24] [25] [26] . On day 6 post-coitus, surrogate mice were injected Trypan blue through tail vein and sacrificed 10 min later to analysis the implantation ability. Recipients and blastocysts used in the blastocyst transfer experiments are list in Tables 2 and 3 .
Statistical analysis
All data were presented as mean ± SEM. The SPSS 11.5 statistical software program was used for statistical analysis.
Percentages were compared between experimental groups and control groups by means of χ 2 test. One-way ANOVA was used for analysis of the relative levels of GRIM-19 mRNA and protein. A value of P<0.05 was considered significant.
Results
Expression of GRIM-19 mRNA in mouse oocytes and preimplantation embryos GRIM-19 mRNA was detected in all developmental stage of mouse oocytes and preimplantation embryos. The expression of GRIM-19 was not different between groups with GV, MI and MII oocytes (Fig. 1a) .
The GRIM-19 mRNA quantity was significantly higher in embryos than in oocytes (P<0.01). In embryos, GRIM-19 mRNA level increased from 2-cell stage to 8-cell stage, then decreased progressively in morulae and blastocyst stage. The expression of GRIM-19 mRNA in the 8-cell stage was significantly higher than that in other stages (Fig. 1a) .
Expression of GRIM-19 protein in mouse oocytes and preimplantation embryos
The GRIM-19 protein expression was found in all developmental stages of mouse oocytes (from GV stage to MII stage) and preimplantation embryos (from 2-cell stage to blastocyst stage). Results confirmed that GRIM-19 at protein levels increased following oocyte maturation, and the expression levels of GRIM-19 in the 8-cell stage were significantly higher than that in other stages (Fig. 1b) .
Localization of GRIM-19 protein by immunofluorescence
Immunofluorescent staining at blastocyst stage showed that GRIM-19 fluorescence labeling primarily in the cytoplasm of all cells investigated, and GRIM-19 display a diffuse pattern throughout the cytoplasm. Merging of GRIM-19 with Mitotracker Red indicated that GRIM-19 is partially localized to the mitochondria (Fig. 2) . These results suggested that the biological roles of GRIM-19 in embryos may associate with its function in mitochondria.
Injection of GRIM-19 siRNA into GV oocytes
To downregulate the expression of GRIM-19 in GV oocyte, we injected GRIM-19 specific siRNA into GV oocytes and evaluated the maturation rate, fertilization rate, cleavage rate, and blastocyst formation rate. After siRNA injection, GV oocytes were cultured individually in 50 μL IVM medium droplets, and the maturity of oocytes was evaluated after 14 h culture. After ICSI, fertilization was inspected for two Table 2 Maturation, development and implantation of mouse GV oocytes after injection with GRIM-19 siRNA(1) or siRNA(2) (2) (Fig. 3) . These results suggested that the downregulation of GRIM-19 expression by GRIM-19 siRNA (1) or siRNA (2) injection was effective. The degeneration rate in the GRIM-19 siRNA(1) and siRNA(2) injected group (Group I, 29.4 %, Group II, 28.2 %, n=1000) was higher than that in control siRNA injected group (Group III, 12.5 %, n=200) and untreated group (Group IV, 8.0 %, n=200) (P<0.05) ( Table 2 ). After IVM, the maturation, fertilization, cleavage, and blastocyst formation rates were significantly lower in the GRIM-19 siRNA(1) and siRNA(2) injected group compared with control siRNA injected group and untreated group (P<0.05, Table 2 , Fig. 3 ). These results indicated that downregulation of GRIM-19 expression impact oocyte viability, oocyte maturation and embryo development.
Microinjection of GRIM-19 antibody into GV oocytes
To investigate the function of GRIM-19 on the maturation and development of oocyte, we injected GRIM-19 antibody into GV stage oocytes and evaluated the maturation rate, fertilization rate, cleavage rate, and blastocyst formation rate. The degeneration rate in the GRIM-19 antibody-injected group (Group I, 23.9 %, n=1000) was higher than that in the rabbit normal IgG -injected group (Group II, 11.5 %, n=200) and untreated group (Group III, 8.0 %, n=200) (P<0.05) ( Table 3) . After IVM, the maturation, fertilization, cleavage, and blastocyst formation rates were significantly lower in the GRIM-19 antibody-injected group compared with rabbit normal IgGinjected group and untreated group (P<0.05, Table 3 , Fig. 4 ). These results indicated that there was a decreased effect of downregulated GRIM-19 on oocyte viability, oocyte maturation and embryo development.
Potential for implantation after microinjection
Blastocysts (n=272) were transferred to the 28 pseudopregnant mice. GRIM-19 siRNA(1) injected group: 20 blastocysts transferred to 2 pseudopregnant mice; GRIM-19 siRNA(2) injected group: 28 blastocysts transferred to 3 pseudopregnant mice; control siRNA injected group: 50 blastocysts transferred to 5 pseudopregnant mice. GRIM-19 antibody injected group: 24 blastocysts transferred to 3 pseudopregnant mice; Rabbit normal IgG injected group: 50 blastocysts transferred to 5 pseudopregnant mice; and untreated control group: 50 blastocysts transferred to 5 pseudopregnant mice (Tables 2 and 3 ). All of 28 recipients were pregnant in at least one horn. The implantation rate of blastocysts derived from the GRIM-19 siRNA injected group was significantly lower than that of control siRNA injected group and untreated group (P<0.05, Table 2 ). The implantation rate of blastocysts derived from the GRIM-19 anitibody microinjected group was significantly lower than that of rabbit normal IgG microinjected group and untreated group (P<0.05, Table 3 , Fig. 4 ). Our findings indicated that downregulation of GRIM-19 reduced the potential of implantation.
Discussion
To date, no reports have been made about the role of GRIM-19 in oogenesis and early embryogenesis, although it has been demonstrated that homozygous deletion mutation of the Grim-19 gene causes embryonic lethality at embryonic day 9.5. Present study provides new insights into function of GRIM-19 on mice oocytes maturation, early embryo development and embryo implantation. As a major outcome, this study confirmed that GRIM-19 expressed in all developmental stages of mouse oocytes (from GV stage to MII stage) and preimplantation embryos (from 2-cell stage to blastocyst stage), evidently indicating the important role of GRIM-19 in oogenesis and early embryogenesis. Simultaneously, by microinjection of GRIM-19 specific siRNA and antibody, we demonstrated that down regulation the expression and activity of GRIM-19 resulted in decreased capacity of oocyte viability, oocyte maturation, embryo development and implantation. Furthermore, we demonstrated that GRIM-19 display a diffuse pattern throughout the cytoplasm, and partially localize to the mitochondria.
Our results indicated that downregulation of GRIM-19 in oocytes reduced oocyte viability and ability of maturation. Most GV oocytes injected with Grim-19 siRNA degenerate in IVM medium. Similarly, almost all the embryos, which fail to develop from Grim 19-depleted oocytes, degenerate in the culture medium. Mitochondria are the most abundant organelles in the mammalian oocyte and preimplantation embryo. Mitochondria are energy supplying organelles in the mammalian oocyte and early embryo, and ATP produced by mitochondria is the major energy source of oocytes and embryos [27, 28] . Mitochondria are maternally inherited, and oocytes contain a pool of non-replicating yet functional mitochondria until the late blastocyst stage [29] . GRIM-19 is one functional component of mitochondria respiratory chain complex I, and is necessary in assembling the complex I-V, transferring proton and maintaining mitochondrial membrane potential (△Ψm). It has been reported that the lack of GRIM-19 could lead to the abnormality of mitochondrion structure, distribution and function [19] . Loss of mitochondria function might potentially lead to cells death. Further studies are needed to detect the mitochondrial membrane potential of oocytes and preimplantation embryos after downregulation of gene expression and activity of GRIM-19.
The cellular location of GRIM-19 is a crucial factor in determining its biological function. GRIM-19 was originally reported as a nuclear protein in HeLa cells [13] . But studies performed by different groups examined the cellular location of GRIM-19 in various cell lines from different species and demonstrated that its primary localization in the cytoplasm [14, 18] . Further results confirmed that GRIM-19 is primarily localized in the mitochondrial complex I [30, 31] . In the present study, we found that GRIM-19 is diffusely distributed throughout the cytoplasm and partially co-localized with the mitochondria of mouse oocytes and preimplantation embryos. Our results confirmed that GRIM-19 was mainly located in cytoplasm of oocytes and embryos, which indicate that its biological roles may associate with its function in mitochondria.
At present, the evaluation of preimplantation embryo is mainly based on morphology [32] [33] [34] . However this evaluation system is not comprehensive. Research shows that damage of mitochondria respiratory chain might reduce ATP production, leading to aneuploidy, interfering the normal fertilization and embryonic development and influencing the development potential of embryos [12] . The low implantation rate is observed in women with advanced maternal age, and it might be related to the low content of ATP in the eggs [35] . The ability of mitochondria to supply ATP is considered the most critical factor for the developmental competence of oocytes and embryos [36] . After downregulation of GRIM-19 in GV oocytes, the in vitro maturation rate was significantly decreased. Meanwhile, the fertilization, cleavage and blastocyst formation rates were also dramatically decreased. These results suggested that downregulation of GRIM-19 in mouse oocytes might interference the oocyte viability, maturation and developmental competence. To further determine the effects of GRIM-19 on embryo implantation, we transfered blastocyst stage embryos to the uterus horns of Fig. 4 Microinjection of GRIM-19 antibody into GV oocytes. a The degeneration, maturation, fertilization, cleavage, and blastocyst formation rates in the GRIM-19 antibody-injected group compared with control group. b Effect of downregulation activity of GRIM-19 on the implantation competence. The implantation rate of blastocysts derived from the GRIM-19 anitibody microinjected group (△) was significantly lower than that of rabbit normal IgG microinjected group (▽) pseudopregnancy mice. Notably, the implantation ratio of blastocysts in the GRIM-19 downregulated group was significantly lower than in the control group. Our results demonstrated that downregulation of GRIM-19 in embryos reduced their implantation potential.
In conclusion, evidence provided in the present study indicated that GRIM-19 expressed in mouse oocytes and preimplantation embryos. GRIM-19 was mainly located in cytoplasm of oocytes and embryos. Downregulation of GRIM-19 in oocytes and embryos reduced oocyte viability, ability of maturation, further development and implantation. Thus, GRIM-19 may play important roles in mouse oogenesis, early embryonic development and implantation. Since downregulation can only provide a partial evaluation of GRIM-19 function, future studies where upregulation of the GRIM-19 is performed are needed to detect the role of GRIM-19 in oogenesis and embryo development.
